KEYNOTE-811

NCT03615326 📎

Regimen

Experimental
pembrolizumab 200 mg + trastuzumab + FP or CAPOX
Control
placebo + trastuzumab + FP or CAPOX

Population

HER2-positive advanced gastric/GEJ cancer as first-line therapy

Key finding

mPFS 10.0 vs 8.1 mo (HR 0.72, 95% CI 0.60-0.87, p=0.0002); mOS 20.0 vs 16.8 mo (HR 0.84); ORR 72.6% vs 60.1%

Source: PMID 37871604

Timeline

    Guideline citations

    • NCCN GASTRIC (p.45)
    • CSCO GASTRIC 2025 (p.81)⚠️ OCR source